Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

11:10 EST 23rd February 2017 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 13,000+

Extremely Relevant

Research shows how protein component of Epstein-Barr virus promotes development of cancer

After an infection with the Epstein-Barr virus (EBV), the virus persists in the body throughout a person's lifetime, usually without causing any symptoms.


Epstein–Barr virus: more than 50 years old and still providing surprises

This Timeline article describes the discovery of the Epstein–Barr virus and summarizes the key advances in the field that have led to our current understanding of the role this virus plays in a number of different lymphoid and epithelial malignancies.

Epstein-Barr virus and cancer: New tricks from an old dog

(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) Approximately 98 percent of all adults are infected with the Epstein-Barr virus. In rare cases, an infection with this virus causes cancer. Scientists at the German Cancer Research Center (DKFZ), at the German Center for Infection Research (DZIF), and at the French Inserm have now discovered that a component of the Epstein-B...


Scientists uncover how common Epstein-Barr virus causes blood cancer in adults and children

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.

Association of Epstein–Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation

EBV-derived microRNAs silence immune alarm signals of the host cell

Epstein-Barr virus (EBV) prevents infected cells from being attacked by the immune system. The virus drives production of small molecules, so-called microRNAs, that suppress alarm signals sent out by the infected cell. Scientists at Helmholtz Zentrum München have elucidated this previously unknown mechanism.

Epstein-Barr virus-positive follicular lymphoma

How a common virus triggers blood cancer

Scientists trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.

Causing Cancer at (a Chromosome's) Arm's Length

Yes, the Epstein-Barr Virus is carcinogenic, but in an unexpected way. Read more...

Common virus triggers blood cancer

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or...

Scientists reveal how a common virus triggers blood cancer

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.

Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and Commit...

Epstein-Barr Virus in Pediatric Patients With Acute B-ALL

What role might regulatory T cells and EBV infection play in the pathogenesis of childhood acute B lymphoblastic leukemia? Journal of Clinical Pathology

How Epstein-Barr Virus Hijacks B Cells To Cause Blood Cancer

Scientists describe a mechanism by which EBV controls the expression of two genes, leading B cells to replicate out of control and avoid apoptosis.

Atara Bio Reaches Agreement with FDA on Design of Phase 3 Trials for its Lead Anti-Cancer Immunotherapy Program, Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, to Support Potential Approval in Two Separate Indicati

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the designs of two Phase 3 trials for ATA 129 intended to supp...

Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein–Barr virus-associated gastric cancer: the prognostic implications

Atara Bio Concludes EMA Scientific Advice and Plans to Submit Conditional Marketing Authorization Application (MAA) in Europe for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL), or ATA 129, for the Treatment of EBV-Associated P

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that pursuant to parallel scientific advice from the European Medicines Agency’s (EMA’s) Scientific...

Aethlon Medical begins sepsis-related virus study

Aethlon Medical has started Sepsis-related virus study, focusing on cytomegalovirus, epstein-barr and herpes simplex viruses.

Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL Outcomes

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.

Highlighting Patient Ethnicity Differences in Epstein-Barr Virus and DLBCL Outcomes

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with Sean Tracy, MD, PhD, at the Mayo Clinic in Rochester, Minnesota.

Advances toward potential Zika virus vaccine development

A promising Zika virus vaccine has now been developed, report scientists. The vaccine, a DNA vaccine, is safer and more effective against Zika virus and could offer more affordable long-term protection, researchers report.

New evidence links Zika, Guillain-Barré syndrome

In a collaborative effort with scientists at six Colombian hospitals, Johns Hopkins researchers report what they believe to be the strongest biological evidence to date linking Zika virus infection and Guillain-Barré syndrome. Epidemiology data have long suggested a close relationship between rising Zika virus infection rates and instances of Guillain-Barré. The new study’s results, ...

More evidence that Zika mRNA vaccines can stop viral replication in mice

(Cell Press) Vaccine developers have successfully protected mice against Zika by injecting synthetic messenger RNA that encodes for virus proteins into the animals. The cells of the mice then build parts of the virus, training the immune system to recognize a future infection. The research, published Feb. 17 in Cell, follows a Feb. 2 Letter in Nature (doi:10.1038/nature21428) that showed similar p...

Zika Virus Infection and Guillain-Barré Syndrome

Guillain-Barré syndrome is a defined complication of Zika virus infection and presents in a typical manner, similar to other post-viral GBS syndromes.

Modifying a live virus in a vaccine to be just strong enough

By genetically tweaking the constituent live virus, scientists have created a vaccine against influenza in which the virus is capable of activating the immune system but cannot replicate in healthy cells -- an approach that may become more widely used for generating live virus vaccines adapted to other viruses.


Quick Search
Advertisement
 

News Quicklinks